CY1125052T1 - Κρυσταλλικες μορφες - Google Patents

Κρυσταλλικες μορφες

Info

Publication number
CY1125052T1
CY1125052T1 CY20221100195T CY221100195T CY1125052T1 CY 1125052 T1 CY1125052 T1 CY 1125052T1 CY 20221100195 T CY20221100195 T CY 20221100195T CY 221100195 T CY221100195 T CY 221100195T CY 1125052 T1 CY1125052 T1 CY 1125052T1
Authority
CY
Cyprus
Prior art keywords
crystal forms
pharmaceutical compositions
crystalline forms
crystalline
phosphono
Prior art date
Application number
CY20221100195T
Other languages
Greek (el)
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CY1125052T1 publication Critical patent/CY1125052T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20221100195T 2016-09-22 2022-03-09 Κρυσταλλικες μορφες CY1125052T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
CY1125052T1 true CY1125052T1 (el) 2024-02-16

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100195T CY1125052T1 (el) 2016-09-22 2022-03-09 Κρυσταλλικες μορφες

Country Status (27)

Country Link
US (4) US10730896B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981774A1 (cg-RX-API-DMAC7.html)
JP (1) JP7097369B2 (cg-RX-API-DMAC7.html)
KR (1) KR102552795B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715639B (cg-RX-API-DMAC7.html)
AU (1) AU2017331930B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037794A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000728A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125052T1 (cg-RX-API-DMAC7.html)
DK (1) DK3515924T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990723A1 (cg-RX-API-DMAC7.html)
ES (1) ES2908572T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220234T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057772T2 (cg-RX-API-DMAC7.html)
IL (1) IL265445B2 (cg-RX-API-DMAC7.html)
LT (1) LT3515924T (cg-RX-API-DMAC7.html)
MA (1) MA46266B1 (cg-RX-API-DMAC7.html)
MX (1) MX381590B (cg-RX-API-DMAC7.html)
MY (1) MY193080A (cg-RX-API-DMAC7.html)
PH (1) PH12019500567B1 (cg-RX-API-DMAC7.html)
PL (1) PL3515924T3 (cg-RX-API-DMAC7.html)
PT (1) PT3515924T (cg-RX-API-DMAC7.html)
RS (1) RS62946B1 (cg-RX-API-DMAC7.html)
SI (1) SI3515924T1 (cg-RX-API-DMAC7.html)
TW (1) TWI752086B (cg-RX-API-DMAC7.html)
UA (1) UA124073C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018055016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
BRPI0617636A2 (pt) 2005-10-21 2012-04-17 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CN102369197B (zh) 2009-04-08 2013-11-06 埃科特莱茵药品有限公司 作为adp受体拮抗剂的6-(3-氮杂-二环[3.1.0]己-3-基)-2-苯基-嘧啶
AU2010240527A1 (en) 2009-04-22 2011-12-01 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as P2Y12 receptor antagonists
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
TW201813965A (zh) 2018-04-16
WO2018055016A1 (en) 2018-03-29
MY193080A (en) 2022-09-26
HRP20220234T1 (hr) 2022-05-13
EP3515924B1 (en) 2021-12-15
IL265445B2 (en) 2024-05-01
US20200017534A1 (en) 2020-01-16
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
CA3037794A1 (en) 2018-03-29
SI3515924T1 (sl) 2022-04-29
US20250163086A1 (en) 2025-05-22
PH12019500567B1 (en) 2024-01-31
HUE057772T2 (hu) 2022-06-28
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
JP2019529553A (ja) 2019-10-17
LT3515924T (lt) 2022-03-10
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
AU2017331930B2 (en) 2021-07-15
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
TWI752086B (zh) 2022-01-11
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
US11365209B2 (en) 2022-06-21
US20210009614A1 (en) 2021-01-14
EA201990723A1 (ru) 2019-10-31
US10730896B2 (en) 2020-08-04
ES2908572T3 (es) 2022-05-03
AU2017331930A1 (en) 2019-03-07
UA124073C2 (uk) 2021-07-14
KR102552795B1 (ko) 2023-07-06
EP3981774A1 (en) 2022-04-13
MA46266B1 (fr) 2022-02-28
BR112019004845A2 (pt) 2019-06-04
CN109715639A (zh) 2019-05-03
IL265445B1 (en) 2024-01-01
JP7097369B2 (ja) 2022-07-07
CN109715639B (zh) 2022-04-19
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
EP3515924A1 (en) 2019-07-31
US12227532B2 (en) 2025-02-18
CL2019000728A1 (es) 2019-07-05

Similar Documents

Publication Publication Date Title
CY1125052T1 (el) Κρυσταλλικες μορφες
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
MX391812B (es) Agonista fxr derivado de esteroides.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA201790275A1 (ru) Кристаллические формы 6-((6,7-диметоксихиназолин-4-ил)окси)-n,2-диметилбензофуран-3-карбоксамида
MX2016014939A (es) Derivados de carboxamida.